Company Profile

Stemline Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers. SL-401 consists of IL-3 recombinantly fused to a truncated diphtheria toxin payload. SL-701 is an immunotherapy designed to activate the immune system to attack tumors. SL-701 comprises various short synthetic peptides that correspond to epitopes of targets, including IL-13 receptor subunit alpha-2 (IL-13Ra2), ephrin type-A receptor 2 (EphA2) and survivin, present on brain cancer. SL-801 is an oral, small molecule that reversibly inhibits Exportin-1 (XPO1), also known as Chromosome Region Maintenance-1 (CRM-1), a nuclear transport protein.

Employees

Sector

Biotechnology & Medical Research

More about the company

06-14	Menarini Group and Stemline Therapeutics, Inc. Reports Data from the Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis	CI
05-28	The Menarini Group and Stemline Therapeutics, Inc. Presents New Data From The Phase 1b/2 ELEVATE Study Of Elacestrant In Combination With Capivasertib In Patients With ER+, HER2- Metastatic Breast Cancer	CI
05-25	Menarini Group Announces New Data At the American Society of Clinical Oncology 2026 Annual Meeting	CI
12-08	Menarini Group and Stemline Therapeutics, Inc. Presents Elacestrant Phase 2 Combination Data in Patients with ER+, HER2- Metastatic Breast Cancer at the 2025 San Antonio Breast Cancer Symposium	CI
11-24	Menarini Group and Stemline Therapeutics, Inc. to Present New Data Related to ELZONRIS	CI
20/03/25	Menarini Group and Stemline Therapeutics Inc. Announce Collaboration with VisualDx to Aid in Identifying People Who May Have Blastic Plasmacytoid Dendritic Cell Neoplasm	CI
11/12/24	Menarini Group Along with Stemline Therapeutics, Inc and Medsir Present the Phase III Study Adela	CI
11/12/23	Menarini Group Presents Initial Safety and Efficacy Data from Phase 1B/2 Elevate and Electra Combination Studies of Orserdu® (Elacestrant) in Patients with Er+, Her2- Metastatic Breast Cancer At the 2023 San Antonio Breast Cancer Symposium	CI
08/12/23	Menarini Group and Stemline Therapeutics, Inc. Presents New Progression-Free Survival Data from Emerald Clinical Study of Orserdu (Elacestrant) in Clinically Relevant Subgroups of Patients with Esr1 Mutations At Sabcs 2023	CI
20/11/23	The Menarini Group and Stemline Therapeutics, Inc. to Present New Data Related to ORSerDU	CI
30/10/23	Quantum Leap Healthcare Collaborative Initiates Landmark Phase 2 RECAST DCIS Platform Trial to Evaluate Alternative DCIS Treatments with Atossa Therapeutics, Havah Therapeutics, and the Menarini Group	CI
20/09/23	European Commission Approves Menarini Group?s ORSERDU (Elacestrant) for the Treatment of Patients with ER+, HER2- Locally Advanced or Metastatic Breast Cancer with an Activating ESR1 Mutation	CI
25/05/23	The Menarini Group and Stemline Therapeutics Announce Results from A New Analysis of the Pivotal EMERALD Clinical Study	CI

17/12/20	Stemline Therapeutics : The Menarini Group received the coveted XV Transatlantic Award from the American Chamber of Commerce in Italy	AQ
10/06/20	STEMLINE THERAPEUTICS INC : Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
11/05/20	STEMLINE THERAPEUTICS : Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	AQ
05/05/20	Stemline Therapeutics : The Menarini Group signs the agreement for the acquisition of Stemline Therapeutics for a maximum consideration of $ 677 million	AQ
04/05/20	STEMLINE THERAPEUTICS INC : Entry into a Material Definitive Agreement, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits (form 8-K)	AQ

16/01/19	Dow Jones Industrial Average : Les valeurs à suivre à Wall Street
16/01/19	USA-Les valeurs à suivre à Wall Street (actualisé)

Manager	Title	Age	Since
Ivan Bergstein CEO	Chief Executive Officer	60	-
David Gionco DFI	Director of Finance/CFO	65	15/01/2014
Jeffrey Levitt CMP	Compliance Officer	-	31/03/2021

Date	Insider	Type	Main position	Quantity	% Market Cap.
10/06/20	Ivan Bergstein	Free	Chief Executive Officer	3,872,092	7.3739%
10/06/20	Robert Francomano	Tender	Executive/Senior Manager	250,891	0.4778%
10/06/20	Ron Bentsur	Tender	Director	151,450	0.2884%

Stemline Therapeutics, Inc. Share Price

Stocks

US85858C1071

Biotechnology & Medical Research

Latest news : Stemline Therapeutics, Inc.

Press Releases : Stemline Therapeutics, Inc.

News in other languages : Stemline Therapeutics, Inc.

Managers and Directors : Stemline Therapeutics, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
STEMLINE THERAPEUTICS, INC.	-.--%	-.--%	-	-	570M
WUXI APPTEC CO., LTD.	+2.02%	+1.26%	+41.37%	+105.18%	67.82B
ARGENX SE	-0.41%	-2.30%	+33.53%	+78.63%	63.22B
INSMED INCORPORATED	-1.11%	+2.78%	-14.86%	+375.59%	27.58B
BIONTECH SE	-4.92%	-3.22%	-3.90%	-17.87%	26.06B
WUXI BIOLOGICS (CAYMAN) INC.	-0.04%	+0.04%	+30.80%	+15.36%	25.38B
GENMAB A/S	+1.12%	+0.84%	+24.50%	-17.84%	19.89B
PHARMAESSENTIA CORPORATION	+6.04%	+7.25%	+233.25%	+383.12%	17.4B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+0.70%	-0.24%	-6.06%	+529.71%	14.95B
EXELIXIS, INC.	-2.27%	+1.37%	+53.01%	+160.83%	14.62B
Average	+0.12%	+1.13%	+43.52%	+179.19%	30.77B
Weighted average by Cap.	+0.20%	+0.44%	+37.65%	+140.73%